Wainscott Capital Founder Shot Dead, Son Arrested

Updated on

Gilbert Sr., who graduated from Princeton University and Harvard Business School began the fund with 2011; the fund has roughly $200 million under management. According to the fund’s website he had, “extensive knowledge of the alternative investment space having spent 40 years on Wall Street with direct investing experience in the stock market, as well as private equity, real estate and the fixed income market.”

Wainscott Capital  – The shooting

Piecing together varied reports and unnamed police sources, Mr. Gilbert was shot once in the head about 3:30 p.m. inside his Turtle Bay apartment. His wife found the body as well as a handgun at the apartment and called 911.

Following the shooting, Gilbert Jr. fled the East Side apartment on foot and fled to his own where he barricaded himself for hours until he was captured by police in riot gear after chopping down his door on W. 18th St.

Following his apprehension and arrest just prior to 11:00PM local time, he was taken stone-faced past reporters en route to the 17th Precinct station house.

Prior to the shooting, the junior Gilbert slinked past the doorman according to varied reports.

“If the doorman had done his job this man would have been alive,” said one neighbor, who only gave his name as Bernard to the New York Daily News.

“I immediately got a bad vibe. The kid got into the elevator before I got the chance to pick up the telephone,” the doorman told police, according to the “Bernard.”

“I don’t care if he said he was his son,” added Bernard. “Five minutes later he comes running out covering his face with a hoodie.”

Wainscott Capital  – Focus on biotech

Prior to his founding of Wainscott Capital Partners in 2011, Gilbert co-founded Syzygy Therapeutics, which focused on the acquisitions of biotech companies.

At Wainscott, Gilbert and his team, which included two biotech PhDs, were known for their steady, yet varied, view of the biotech sector and traditionally held 40 long and 20 short positions in its portfolio.

“For the next 10 years we really have the wind at our back. There is a continually expanding universe of companies that are executing, and the reason they are executing is that there have been some major breakthroughs in science. There are new drugs out there and new treatments for diseases,” Gilbert said in a November interview with FINalternatives.

Leave a Comment